Moderate
Suspected
Description
Fluoxetine plus sumatriptan may potentiate serotonin syndrome risk, though the clinical evidence is mixed and the absolute risk is debated.
Mécanisme
Fluoxetine inhibits serotonin reuptake and is a potent CYP2D6 inhibitor which may modestly increase sumatriptan exposure; combined serotonergic activity raises theoretical serotonin syndrome risk.
Signification clinique
Post-marketing surveillance reports exist; many clinical guidelines permit the combination with monitoring, given frequent co-prescription in migraine.
Prise en charge
Combination is commonly used; monitor for signs of serotonin syndrome especially at treatment initiation or dose escalation.